INT21552

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1990
Last Reported 2010
Negated 0
Speculated 3
Reported most in Abstract
Documents 10
Total Number 13
Disease Relevance 3.70
Pain Relevance 6.05

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Drd1a) endoplasmic reticulum (Drd1a) plasma membrane (Drd1a)
nucleus (Drd1a) intracellular (Drd1a) signal transducer activity (Drd1a)
Anatomy Link Frequency
neurons 2
output neurons 1
nucleus accumbens 1
striatum 1
Drd1a (Mus musculus)
Pain Link Frequency Relevance Heat
Dopamine 102 100.00 Very High Very High Very High
agonist 9 100.00 Very High Very High Very High
Antinociceptive 2 99.98 Very High Very High Very High
Morphine 29 99.20 Very High Very High Very High
Nucleus accumbens 42 98.44 Very High Very High Very High
Serotonin 10 98.16 Very High Very High Very High
tolerance 2 96.56 Very High Very High Very High
Analgesic 1 95.20 Very High Very High Very High
Neuropeptide 7 94.96 High High
antagonist 12 92.32 High High
Disease Link Frequency Relevance Heat
Schizophrenia 220 99.84 Very High Very High Very High
Targeted Disruption 95 98.88 Very High Very High Very High
Nociception 1 97.32 Very High Very High Very High
Neurodegenerative Disease 9 94.60 High High
Congenital Anomalies 46 88.60 High High
Disease 82 82.56 Quite High
Cognitive Disorder 11 80.60 Quite High
Dystonia 10 74.64 Quite High
Sprains And Strains 13 61.48 Quite High
Stress 15 46.88 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The generation of BAC transgenic mice expressing DARPP-32 with different tags under the control of drd1a and drd2 promoters allowed the analysis of DARPP-32 phosphorylation selectively in the two populations of striatal output neurons in vivo (Bateup et al., 2008) (Figure 1).
Regulation (control) of drd1a in output neurons associated with targeted disruption
1) Confidence 0.57 Published 2010 Journal Frontiers in Neuroanatomy Section Body Doc Link PMC2955397 Disease Relevance 0.10 Pain Relevance 0.07
However, our previous study did not determine whether all DARPP-32-positive cells expressed EGFP under the control of either drd1a or drd2 promoter.
Spec (whether) Regulation (control) of drd1a
2) Confidence 0.44 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2651623 Disease Relevance 0.29 Pain Relevance 0
The dopamine D1 receptor agonist SKF 38393 was ineffective on this parameter.
Regulation (ineffective) of D1 receptor associated with dopamine and agonist
3) Confidence 0.36 Published 1990 Journal Eur. J. Pharmacol. Section Abstract Doc Link 2176983 Disease Relevance 0.10 Pain Relevance 0.80
A single injection of 1.25 mg/kg and 2.5 mg/kg morphine resulted in a stronger antinociceptive response in D1 receptor deficient mice than in wild-type animals.
Regulation (response) of D1 receptor associated with antinociceptive and morphine
4) Confidence 0.27 Published 2001 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 11383718 Disease Relevance 0 Pain Relevance 0.80
Six C57Bl/6J–Swiss Webster hybrid transgenic mice carrying BAC that express enhanced green fluorescent protein (BAC-EGFP) under the control of D1R promoter (drd1a-EGFP) or D2R promoter (drd2-EGFP) were used for characterization of striatonigral and striatopallidal specificity of labeling.
Regulation (control) of drd1a associated with targeted disruption
5) Confidence 0.27 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2651623 Disease Relevance 0.32 Pain Relevance 0
Six C57Bl/6J–Swiss Webster hybrid transgenic mice carrying BAC that express enhanced green fluorescent protein (BAC-EGFP) under the control of D1R promoter (drd1a-EGFP) or D2R promoter (drd2-EGFP) were used for characterization of striatonigral and striatopallidal specificity of labeling.
Regulation (control) of drd1a associated with targeted disruption
6) Confidence 0.27 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2651623 Disease Relevance 0.32 Pain Relevance 0
A separate quantitative PCR analysis of genes in the last of these groups confirms the dysregulation of both orphan (Gpr88) and known (DrD1A, Adora2A, Cnr1, Grm5, Gpr6) G protein-coupled receptors, scaffolding (PSD95, Homer1) and signaling (Sgk, Cap1) proteins, and neuropeptides (CCK, galanin).
Regulation (dysregulation) of DrD1A associated with neuropeptide
7) Confidence 0.26 Published 2008 Journal Eur. J. Neurosci. Section Abstract Doc Link 18588537 Disease Relevance 0.18 Pain Relevance 0.74
Using transgenic mice with enhanced green fluorescent protein (EGFP) expression under the control of the dopamine D1 receptor (D1R) (Drd1a-EGFP) or D2 receptor promoter (Drd2-EGFP) we show that context-dependent ERK phosphorylation is restricted to D1R-expressing medium spiny neurons.
Regulation (control) of dopamine D1 receptor in neurons associated with targeted disruption and dopamine
8) Confidence 0.23 Published 2008 Journal Neuropharmacology Section Abstract Doc Link 18614186 Disease Relevance 0.10 Pain Relevance 0.59
The blocking effect of SCH23390 on the morphine-conditioned place preference suggests that mu 2 receptors may regulate the dopaminergic system, especially dopamine D1 receptors, and are also involved in the reinforcing effects of morphine.
Spec (may) Regulation (regulate) of dopamine D1 associated with dopamine and morphine
9) Confidence 0.18 Published 1993 Journal Brain Res. Section Abstract Doc Link 8383571 Disease Relevance 0 Pain Relevance 1.19
Total and subregional analysis of the striatum and nucleus accumbens showed that D-2 receptor ([3H]spiperone) binding density was increased while D-1 receptor ([3H]SCH 23390) and D-3 receptor ([3H]7-OH-DPAT) binding density was not altered.
Regulation (altered) of D-1 receptor in striatum associated with nucleus accumbens
10) Confidence 0.06 Published 2004 Journal Exp. Neurol. Section Abstract Doc Link 15530890 Disease Relevance 0.34 Pain Relevance 0.61
Dimebon also had significant effect on Dopamine D1, D2S, D3 receptors, Imidazoline I2 receptor, Serotonin 5-HT2 and 5-HT2B receptors.
Regulation (effect) of Dopamine D1 associated with dopamine and serotonin
11) Confidence 0.02 Published 2008 Journal Mol Neurodegener Section Body Doc Link PMC2577671 Disease Relevance 0.70 Pain Relevance 0.18
Total and subregional analysis of the striatum and nucleus accumbens showed that D-2 receptor ([3H]spiperone) binding density was increased while D-1 receptor ([3H]SCH 23390) and D-3 receptor ([3H]7-OH-DPAT) binding density was not altered.
Regulation (altered) of D-1 receptor in nucleus accumbens associated with nucleus accumbens
12) Confidence 0.02 Published 2004 Journal Exp. Neurol. Section Abstract Doc Link 15530890 Disease Relevance 0.34 Pain Relevance 0.61
There is a well-known association of enhanced DA D2 function in schizophrenia, and the D1A receptor function may also be abnormal in schizophrenia.165 The level of expression of DA transporter is possibly an illness trait in schizophrenia,166 and mouse models of schizophrenia have reduced expression of DA transporter.167 Increased transcription of TH in the substantia nigra is also found in schizophrenia,168 and transgenic mice used as animal models of schizophrenia have reduced density and numbers of TH neurons in the substantia nigra pars compacta.169
Spec (may) Regulation (abnormal) of D1A receptor in neurons associated with targeted disruption, dopamine, substantia nigra and schizophrenia
13) Confidence 0.01 Published 2009 Journal Schizophrenia Bulletin Section Body Doc Link PMC2643957 Disease Relevance 0.91 Pain Relevance 0.46

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox